142 related articles for article (PubMed ID: 30446313)
1. Discovery of naldemedine: A potent and orally available opioid receptor antagonist for treatment of opioid-induced adverse effects.
Inagaki M; Kume M; Tamura Y; Hara S; Goto Y; Haga N; Hasegawa T; Nakamura T; Koike K; Oonishi S; Kanemasa T; Kai H
Bioorg Med Chem Lett; 2019 Jan; 29(1):73-77. PubMed ID: 30446313
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological Profile of Naldemedine, a Peripherally Acting
Kanemasa T; Koike K; Takase K; Arai T; Nakamura A; Morioka Y; Hasegawa M
J Pharmacol Exp Ther; 2020 Jun; 373(3):438-444. PubMed ID: 32169839
[TBL] [Abstract][Full Text] [Related]
3. Preventive effects of naldemedine, peripherally acting μ-opioid receptor antagonist, on morphine-induced nausea and vomiting in ferrets.
Kanemasa T; Matsuzaki T; Koike K; Hasegawa M; Suzuki T
Life Sci; 2020 Sep; 257():118048. PubMed ID: 32622946
[TBL] [Abstract][Full Text] [Related]
4. SoRI 9409, a non-peptide opioid mu receptor agonist/delta receptor antagonist, fails to stimulate [35S]-GTP-gamma-S binding at cloned opioid receptors.
Xu H; Lu YF; Rice KC; Ananthan S; Rothman RB
Brain Res Bull; 2001 Jul; 55(4):507-11. PubMed ID: 11543951
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
[TBL] [Abstract][Full Text] [Related]
6. A meta-analysis of naldemedine for the treatment of opioid-induced constipation.
Song X; Wang D; Qu X; Dong N; Teng S
Expert Rev Clin Pharmacol; 2019 Feb; 12(2):121-128. PubMed ID: 30652502
[TBL] [Abstract][Full Text] [Related]
7. Augmentation of spinal morphine analgesia and inhibition of tolerance by low doses of mu- and delta-opioid receptor antagonists.
Abul-Husn NS; Sutak M; Milne B; Jhamandas K
Br J Pharmacol; 2007 Jul; 151(6):877-87. PubMed ID: 17502848
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, modeling, and pharmacological evaluation of UMB 425, a mixed μ agonist/δ antagonist opioid analgesic with reduced tolerance liabilities.
Healy JR; Bezawada P; Shim J; Jones JW; Kane MA; MacKerell AD; Coop A; Matsumoto RR
ACS Chem Neurosci; 2013 Sep; 4(9):1256-66. PubMed ID: 23713721
[TBL] [Abstract][Full Text] [Related]
9. Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials.
Hale M; Wild J; Reddy J; Yamada T; Arjona Ferreira JC
Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):555-564. PubMed ID: 28576452
[TBL] [Abstract][Full Text] [Related]
10. Naldemedine: Peripherally Acting Opioid Receptor Antagonist for Treating Opioid-induced Adverse Effects.
Inagaki M; Kanemasa T; Yokota T
Curr Top Med Chem; 2020; 20(31):2830-2842. PubMed ID: 32648846
[TBL] [Abstract][Full Text] [Related]
11. Prevention and management of diarrhea associated with naldemedine among patients receiving opioids: a retrospective cohort study.
Takagi Y; Osawa G; Kato Y; Ikezawa E; Kobayashi C; Aruga E
BMC Gastroenterol; 2020 Jan; 20(1):25. PubMed ID: 32005157
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the development of morphine tolerance by a potent dual mu-delta-opioid antagonist, H-Dmt-Tic-Lys-NH-CH2-Ph.
Jinsmaa Y; Marczak ED; Balboni G; Salvadori S; Lazarus LH
Pharmacol Biochem Behav; 2008 Oct; 90(4):651-7. PubMed ID: 18571706
[TBL] [Abstract][Full Text] [Related]
13. Minimal contribution of P-gp on the low brain distribution of naldemedine, a peripherally acting μ-opioid receptor antagonist.
Watari R; Matsuda A; Ohnishi S; Hasegawa H
Drug Metab Pharmacokinet; 2019 Apr; 34(2):126-133. PubMed ID: 30770183
[TBL] [Abstract][Full Text] [Related]
14. Intracerebroventricular administration of CYX-6, a potent μ-opioid receptor agonist, a δ- and κ-opioid receptor antagonist and a biased ligand at μ, δ & κ-opioid receptors, evokes antinociception with minimal constipation and respiratory depression in rats in contrast to morphine.
Imam MZ; Kuo A; Ghassabian S; Cai Y; Qin Y; Li T; Smith MT
Eur J Pharmacol; 2020 Mar; 871():172918. PubMed ID: 31958457
[TBL] [Abstract][Full Text] [Related]
15. Differential modulation of mu- and delta-opioid antinociception by neuropeptide FF receptors in young mice.
Desprat C; Zajac JM
Neuropeptides; 1997 Feb; 31(1):1-7. PubMed ID: 9574828
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic effects of naldemedine, a peripherally acting μ-opioid receptor antagonist, in in vitro and in vivo models of opioid-induced constipation.
Kanemasa T; Koike K; Arai T; Ono H; Horita N; Chiba H; Nakamura A; Morioka Y; Kihara T; Hasegawa M
Neurogastroenterol Motil; 2019 May; 31(5):e13563. PubMed ID: 30821019
[TBL] [Abstract][Full Text] [Related]
17. Discovery of two novel branched peptidomimetics containing endomorphin-2 and RF9 pharmacophores: Synthesis and neuropharmacological evaluation.
Zhang T; Han Z; Shi X; Zhao W; Wang Z; Zhang R; Xu B; Zhang M; Zhang Q; Xiao J; Zhu H; Zheng T; Fang Q
Bioorg Med Chem; 2019 Feb; 27(4):630-643. PubMed ID: 30626554
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity to μ-opioid receptor-mediated anti-nociception is determined by cross-regulation between μ- and δ-opioid receptors at supraspinal level.
Ballesta JJ; Cremades J; Rodríguez-Muñoz M; Garzón J; Faura CC
Br J Pharmacol; 2012 May; 166(1):309-26. PubMed ID: 22023056
[TBL] [Abstract][Full Text] [Related]
19. The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Naldemedine.
Fukumura K; Yamada T; Yokota T; Kawasaki A
Clin Pharmacol Drug Dev; 2020 Feb; 9(2):162-174. PubMed ID: 30977959
[TBL] [Abstract][Full Text] [Related]
20. Characterisation of opioid receptors involved in modulating circular and longitudinal muscle contraction in the rat ileum.
Gray AC; White PJ; Coupar IM
Br J Pharmacol; 2005 Mar; 144(5):687-94. PubMed ID: 15678085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
